Lv4
680 积分 2024-07-24 加入
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer
19小时前
已完结
Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer
7天前
已完结
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
7天前
已完结
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
7天前
已完结
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
8天前
已完结
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
10天前
已完结
Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: a network meta-analysis
10天前
已完结
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine-oxaliplatin versus short-course radiotherapy followed by capecitabine-oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial
15天前
已完结
The next generation of immunotherapies for lung cancers
18天前
已完结
EGFR-mutated NSCLC: A roadmap to treatment sequences
18天前
已完结
皖公网安备34019202002308
